2017 will be a year of equilibrium for medical costs. Forces that increase health costs are tempered by demand for value in the New Health Economy. PwC’s HRI projects a 6.5% growth rate for medical costs for 2017, the same as the current year.
Healthcare organizations with evidence that their population health programs are working well on a large scale are more likely to be rewarded in value-based deals.
Half of US health systems are contemplating owning a health plan. What should they consider?
Retail pharmacies face shrinking margins in their core business and tougher competition in a shifting health industry. Yet these companies have the opportunity to redefine themselves as central players – and critical partners – in the New Health Economy.
Five independent groups have developed frameworks to assess the value of prescription drugs. The assessment results are filtering into business and clinical practices in the New Health Economy.
Parts of the pharmaceutical industry continue to struggle with drug quality. A major shift in the way the FDA oversees drug quality could pose new challenges for companies with inadequate control over their manufacturing facilities and supply chains.
Carriers are refining their product offerings as they become more knowledgeable about who they are insuring and how to navigate a more tightly regulated market. With real money left to capture, there is still opportunity for insurers to enter the market or expand their footprints.
2016 will be a year of firsts for healthcare consumers, organizations and new entrants as innovative tools and services enter the New Health Economy. HRI’s annual Top health industry issues report highlights the forces that are expected to have the most impact on the industry in the coming year, with a glance back at key trends from the past decade.
Forecasts of physician shortages are based on outdated care delivery models. In the New Health Economy, with purchasers demanding greater value, do-it-yourself consumers and integrated care teams armed with a black bag of virtual tools are poised to reinvent primary care and close the gap.
As public and private insurers move away from traditional fee-for-service payments, healthcare organizations are struggling to make the leap. Market share, regional characteristics and an organization's mission and culture all play a role.
New collaborations pairing drug makers with insurers, health systems, patient groups and technology firms are reconfiguring drug R&D and commercialization. Shared data is shaping drug development and demonstrating health outcomes to create value for patients and industry.
New entrants are poised to draw billions of dollars in revenue from traditional organizations while building lucrative new markets in the burgeoning New Health Economy™. Here's how.